

## Anti-PD-L1 Humanized Antibody

<b>CATALOG NO:</b>	A1305-100
<b>ALTERNATE NAMES:</b>	CD274, Programmed Cell Death 1 Ligand 1, B7H1
<b>AMOUNT:</b>	100 µg
<b>IMMUNOGEN:</b>	Human programmed cell death 1 ligand 1 (PD-L1)
<b>HOST/ISOTYPE:</b>	Human IgG1
<b>CLONALITY:</b>	Monoclonal
<b>SOURCE:</b>	CHO cells
<b>ENDOTOXIN LEVELS:</b>	≤ 1 EU/mg
<b>CAS NO.:</b>	1380723-44-3
<b>SPECIES REACTIVITY:</b>	Human
<b>FORM:</b>	Liquid
<b>FORMULATION:</b>	Supplied in phosphate buffered saline, pH 7.2
<b>STORAGE CONDITIONS:</b>	Store the undiluted solution at 4 °C in the dark. Avoid repeated freeze-thaw cycles
<b>SPECIFICITY:</b>	The research-grade biosimilar is deficient in binding to FCγR, and therefore does not cause antibody-dependent cell-mediated cytotoxicity. The humanized antibody blocks the interaction of PD-L1 with both PD-1 and B7.1, but does not block the interaction of PD-L2 with PD-1.
<b>DESCRIPTION:</b>	This research-grade biosimilar is a fully-humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). PD-L1 is an immune inhibitory receptor ligand that is expressed by T and B lymphocytes, as well as various types of tumor cells to escape immune surveillance. The antibody blocks the interaction of PD-L1 with PD-1 and induces anti-tumor immune reactivation.

**Note: This information is only intended as a guide. The optimal dilutions must be determined by the user.**

### RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), Humanized Antibody (**Cat. No. A1045-100**)
- Anti-EGFR (Cetuximab), Chimeric Antibody (**Cat. No. A1047-100**)
- Anti-HER2 Humanized Antibody (**Cat. No. A1046-100**)
- Anti-CD20 (Rituximab), Chimeric Antibody (**Cat. No. A1049-100**)
- Anti-EGFR (Panitumumab), Humanized Antibody (**Cat. No. A1050-100**)
- Anti-PD-1 (Pembrolizumab), Humanized Antibody (**Cat. No. A1306-100**)
- Anti-PD-1 (Nivolumab), Humanized Antibody (**Cat. No. A1307-100**)

**FOR RESEARCH USE ONLY! Not to be used on humans.**